Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for MYC / BCL2 double-hit ( MYC / BCL2 -DH). The genetic basis underlying...
Gespeichert in:
Veröffentlicht in: | Leukemia 2020-05, Vol.34 (5), p.1329-1341 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for
MYC
/
BCL2
double-hit (
MYC
/
BCL2
-DH). The genetic basis underlying MHG-DLBCL and their aggressive clinical behaviour remain unknown. We investigated 697 cases of DLBCL, particularly those with
MYC
/
BCL2
-DH (
n
= 62) by targeted sequencing and gene expression profiling. We showed that DLBCL with
MYC
/
BCL2
-DH, and those with
BCL2
translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade transformation. We identified frequent
MYC
hotspot mutations that affect the phosphorylation site (T58) and its adjacent amino acids, which are important for MYC protein degradation. These
MYC
mutations were seen in a subset of cases with
MYC
translocation, but predominantly in those of MHG. The mutations were more frequent in double-hit lymphomas with IG as the
MYC
translocation partner, and were associated with higher MYC protein expression and poor patient survival. DLBCL with
MYC
/
BCL2
-DH and those with
BCL2
translocation alone are most likely derived from follicular lymphoma or its precursor lesion, and acquisition of
MYC
pathogenic mutations may augment MYC function, resulting in aggressive clinical behaviour. |
---|---|
ISSN: | 0887-6924 1476-5551 |
DOI: | 10.1038/s41375-019-0691-6 |